Neutrophils and their extracellular traps in MS pathology

Our project investigates novel NLRP3 inhibitors to understand their efficacy in human cells and preclinical models of chronic inflammatory diseases.

Novel computational methods for long-read sequencing

We are exploring a number of therapeutic options, developed at ANU and by commercial partners, which include gene-based therapies, non-invasive therapeutics (including the use of low-level laser therapy using red light) and novel compounds.

We study how nuclear RNAs are processed, surveilled, and selectively exported, and how non-coding RNAs and R-loops shape genome organisation and stability. By defining the logic of nuclear RNA fate decisions, we aim to understand how RNA systems maintain genome integrity and contribute to disease.

Optimising the dose of 670nm light therapy for treatment of retinal degenerations

This project investigates miRNA profiles in human trabecular bone, synovial fluid and plasma sourced from total join replacement revision surgery, to develop better markers, treatments and prevention strategies.

Pathogenic effects of cancer-associated mutations in IRF4

Investigating the role of Spindle-E Zinc Finger motif in piRNA ping-pong biogenesis

RNA Sequencing with Oxford Nanopore Technologies produces a stream of signals that can be decoded to uncover the properties of individual molecules.

We engineer programmable RNA systems that activate gene expression only in target cells by embedding sensing and logic directly within mRNAs. Using ribozyme-based RNA switches, we create self-activating mRNA platforms that enable precise, cell-specific control of gene expression for biomedical applications.

Quantitative studies of the presentation of viral antigens to the immune system (especially CD8+ T cells) during infection.